MarketLens

Pricing Plans Sign Up Log in

Stock Analysis Pro

What Did Ascentage Pharma Present at ASCO 2026

8 hours ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

What Did D3 Bio Present at ASCO 2026 for Elisrasib

1 hour ago

What Makes Elisrasib's ASCO 2026 Data So Significant

1 hour ago

What's Behind the Recent Insider Selling at NewAmsterdam Pharma (NAMS)

3 months ago

What Makes Akeso's ASCO 2026 Plenary Session So Crucial

5 days ago

Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026

Summit Therapeutics presented Phase II data for ivonescimab in first-line metastatic colorectal cancer at ASCO 2026. The AK112-206 trial results provide early clinical evidence for the drug's efficacy...

SMMT

Stock News•1 week ago

Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026

Ascentage Pharma released six clinical study abstracts for the 2026 ASCO Annual Meeting, featuring three lead drug candidates. Three of these studies were selected for rapid oral presentations, highli...

AAPG

Stock News•1 week ago

Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

Pliant Therapeutics will present data from its Phase 1b FORTIFY trial at the 2026 ASCO Annual Meeting in Chicago, running May 29 to June 2. The presentation highlights PLN-101095 in patients with ICI-...

PLRX

Stock News•1 week ago

Legend Biotech Announces Presentations at ASCO 2026

Legend Biotech will present preliminary Phase 1 data for its investigational DLL3-targeted CAR-T therapy, LB2102, at the 2026 ASCO Annual Meeting. The presentation highlights the company's progress in...

LEGN